董事介绍
注:董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Cary G. Vance | 男 | Director, President and Chief Executive Officer | 50 | 207.74万美元 | 未持股 | 2016-05-31 |
| Christopher P. Lowe | 男 | Interim Chief Financial Officer and Director | 48 | 28.26万美元 | 未持股 | 2016-05-31 |
| Kevin Hykes | 男 | Director | 50 | 8.28万美元 | 未持股 | 2016-05-31 |
| William R. Rohn | 男 | Director | 72 | 8.88万美元 | 未持股 | 2016-05-31 |
| Michael L. Eagle | 男 | Director | 68 | 12.07万美元 | 未持股 | 2016-05-31 |
| Nadim Yared | 男 | Director | 48 | 8.08万美元 | 未持股 | 2016-05-31 |
| Stephen Newman | 男 | Director | 65 | 9.46万美元 | 未持股 | 2016-05-31 |
| Marjorie L. Bowen | 女 | Director | 51 | 9.56万美元 | 未持股 | 2016-05-31 |
高管介绍
注:高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Cary G. Vance | 男 | Director, President and Chief Executive Officer | 50 | 207.74万美元 | 未持股 | 2016-05-31 |
| Brian Sheahan | 男 | Vice President, Regulatory, Clinical and Quality Affairs | 51 | 59.66万美元 | 未持股 | 2016-05-31 |
| Christopher P. Lowe | 男 | Interim Chief Financial Officer and Director | 48 | 28.26万美元 | 未持股 | 2016-05-31 |
| Robert Cathcart | 男 | Senior Vice President of Global Sales | 55 | 52.33万美元 | 未持股 | 2016-05-31 |
董事简历
中英对照 |  中文 |  英文- Cary G. Vance
-
Cary G. Vance,2014年5月起,担任本公司的总裁、首席执行官、董事。2011年5月至2014年5月,他担任Teleflex Incorporated麻醉和呼吸的全球业务总裁,这是专有医疗器械公司;2010年2月至2011年5月,担任北美地区执行副总裁。他于2007年加入Covidien,担任副总裁、基于能源设备的总经理,这是全球性的医疗保健产品制造商;2008年,担任副总裁、美洲地区介入式肿瘤总经理。1997-2007,他在 GE Healthcare担任了愈益重要的多个职务,主要涉及诊断成像的销售、销售与营销管理、执行领导。他在Marquette University获得经济学士学位、工商管理硕士学位。
Cary G. Vance has served as our President and Chief Executive Officer, and as a member of our Board, since May 2014. Mr. Vance served as President of the Anesthesia & Respiratory global business at Teleflex Incorporated, a specialty medical device company, from May 2011 until May 2014 and as their Executive Vice President North America from February 2010 to May 2011. Mr. Vance joined Covidien, a global health care products company and manufacturer, in 2007 as Vice President & General Manager for their Energy-based Devices and was appointed as Vice President & General Manager of Interventional Oncology - Americas in 2008. Mr. Vance served in a series of roles with progressive responsibility at GE Healthcare from 1997 to 2007 principally in diagnostic imaging sales, sales and marketing management and executive leadership. Mr. Vance holds a B.A. in Economics and an M.B.A. from Marquette University. Mr. Vance’s executive experience in the medical device space contributed to our conclusion that he should serve as a director. - Cary G. Vance,2014年5月起,担任本公司的总裁、首席执行官、董事。2011年5月至2014年5月,他担任Teleflex Incorporated麻醉和呼吸的全球业务总裁,这是专有医疗器械公司;2010年2月至2011年5月,担任北美地区执行副总裁。他于2007年加入Covidien,担任副总裁、基于能源设备的总经理,这是全球性的医疗保健产品制造商;2008年,担任副总裁、美洲地区介入式肿瘤总经理。1997-2007,他在 GE Healthcare担任了愈益重要的多个职务,主要涉及诊断成像的销售、销售与营销管理、执行领导。他在Marquette University获得经济学士学位、工商管理硕士学位。
- Cary G. Vance has served as our President and Chief Executive Officer, and as a member of our Board, since May 2014. Mr. Vance served as President of the Anesthesia & Respiratory global business at Teleflex Incorporated, a specialty medical device company, from May 2011 until May 2014 and as their Executive Vice President North America from February 2010 to May 2011. Mr. Vance joined Covidien, a global health care products company and manufacturer, in 2007 as Vice President & General Manager for their Energy-based Devices and was appointed as Vice President & General Manager of Interventional Oncology - Americas in 2008. Mr. Vance served in a series of roles with progressive responsibility at GE Healthcare from 1997 to 2007 principally in diagnostic imaging sales, sales and marketing management and executive leadership. Mr. Vance holds a B.A. in Economics and an M.B.A. from Marquette University. Mr. Vance’s executive experience in the medical device space contributed to our conclusion that he should serve as a director.
- Christopher P. Lowe
-
Christopher P. Lowe, 他一直担任我们的董事会成员(2006年9月以来),以及我们的临时首席执行官(2014年2月以来)。他曾担任Anthera Pharmaceuticals公司(药物开发公司)的行政副总裁和首席财务官(从2007年11月到2013年6月),以及其首席商务官(从2011年1月到2013年6月)。离开Anthera公司以后,他曾担任生命科学公司的独立顾问,直到加入FLG Partners公司(首席财务官咨询、服务和咨询公司),并于2014年1月当选合伙人。他曾担任Asthmatx公司(医疗器械公司)的副总裁,负责财务和行政(2005年9月以来),以及其首席财务官(从2006年1月到2007年11月)。他也曾任职Pacific Pharmaceutical Services公司(cGMP实体,提供温度控制存储、粉调剂、内部标签印刷和临床试验材料标签、临床销售物流和CMC咨询服务,服务制药行业、临床研究和学术实验室)的董事会。他持有California Polytechnic State University(位于圣路易斯奥比斯波)的学士学位,以及Saint Mary’s University(位于德克萨斯)的工商管理硕士学位。
Christopher P. Lowe has served as a member of our Board since September 2006 as our Interim Chief Executive Officer from February 2014 to May 2014 and our Interim Chief Financial Officer since June 2014. Mr. Lowe served as Vice President, Administration and Chief Financial Officer of Anthera Pharmaceuticals, Inc., a drug development company, from November 2007 through June 2013 and additionally served as its Chief Business Officer from January 2011 until June 2013. Since leaving Anthera, Mr. Lowe was an independent consultant to life sciences companies until joining FLG Partners, LLC, a CFO consulting, services and board advisory firm, as a partner in January 2014. Mr. Lowe served as Vice President, Finance and Administration of Asthmatx, Inc., a medical device company, since September 2005 and as its Chief Financial Officer from January 2006 to November 2007. Mr. Lowe also serves on the board of Pacific Pharmaceutical Services, a cGMP facility providing temperature controlled storage, powder dispensing, in-house label printing and clinical trial materials labeling, clinical distribution logistics and CMC advisory services to the pharmaceutical industry, clinical researchers and academic laboratories. Mr. Lowe holds a B.S. from California Polytechnic State University, San Luis Obispo and an M.B.A. from Saint Mary’s University, Texas. - Christopher P. Lowe, 他一直担任我们的董事会成员(2006年9月以来),以及我们的临时首席执行官(2014年2月以来)。他曾担任Anthera Pharmaceuticals公司(药物开发公司)的行政副总裁和首席财务官(从2007年11月到2013年6月),以及其首席商务官(从2011年1月到2013年6月)。离开Anthera公司以后,他曾担任生命科学公司的独立顾问,直到加入FLG Partners公司(首席财务官咨询、服务和咨询公司),并于2014年1月当选合伙人。他曾担任Asthmatx公司(医疗器械公司)的副总裁,负责财务和行政(2005年9月以来),以及其首席财务官(从2006年1月到2007年11月)。他也曾任职Pacific Pharmaceutical Services公司(cGMP实体,提供温度控制存储、粉调剂、内部标签印刷和临床试验材料标签、临床销售物流和CMC咨询服务,服务制药行业、临床研究和学术实验室)的董事会。他持有California Polytechnic State University(位于圣路易斯奥比斯波)的学士学位,以及Saint Mary’s University(位于德克萨斯)的工商管理硕士学位。
- Christopher P. Lowe has served as a member of our Board since September 2006 as our Interim Chief Executive Officer from February 2014 to May 2014 and our Interim Chief Financial Officer since June 2014. Mr. Lowe served as Vice President, Administration and Chief Financial Officer of Anthera Pharmaceuticals, Inc., a drug development company, from November 2007 through June 2013 and additionally served as its Chief Business Officer from January 2011 until June 2013. Since leaving Anthera, Mr. Lowe was an independent consultant to life sciences companies until joining FLG Partners, LLC, a CFO consulting, services and board advisory firm, as a partner in January 2014. Mr. Lowe served as Vice President, Finance and Administration of Asthmatx, Inc., a medical device company, since September 2005 and as its Chief Financial Officer from January 2006 to November 2007. Mr. Lowe also serves on the board of Pacific Pharmaceutical Services, a cGMP facility providing temperature controlled storage, powder dispensing, in-house label printing and clinical trial materials labeling, clinical distribution logistics and CMC advisory services to the pharmaceutical industry, clinical researchers and academic laboratories. Mr. Lowe holds a B.S. from California Polytechnic State University, San Luis Obispo and an M.B.A. from Saint Mary’s University, Texas.
- Kevin Hykes
-
Kevin Hykes,Hykes先生在自2009年7月起,一直是我们董事会的成员。Hykes先生目前是Versant Ventures的一名运营合伙人和Metavention, Inc.(一家发展早期的医疗设备公司,专注于研发2型糖尿病的介入治疗产品)的董事长和首席执行官。2010年3月到2012年12月期间,Hykes先生曾是 Cameron Health, Inc.(一家植入式除颤器公司,在2012年6月的时候被 Boston Scientific Corporation收购)的总裁和首席执行官;2008年5月到2010年3月期间,Hykes先生曾在Visiogen, Inc.(一家白内障和屈光患者产品的研发商,在2009年10月的时候被Abbott Laboratories收购)担任首席商务官。此前,Hykes先生曾在1992年到2008年期间受雇与Medtronic, Inc.,期间在2005年12月到2008年5月期间担任医疗卫生系统的副总裁;在2003年5月到2005年12月期间,担任心力衰竭相关业务的副总裁。Hykes先生拥有威斯康星大学麦迪逊分校(University of Wisconsin,Madison)的工商管理学士学位和西北大学凯洛格管理学院(the J.L. Kellogg Graduate School of Management at Northwestern University)的工商管理硕士学位。
Kevin Hykes has served as a member of our Board since July 2009. Since August 2013 Mr. Hykes has served as an Operating Partner at Versant Ventures and the Chairman and CEO of Metavention, Inc., an early-stage medical device company focused on the development of interventional therapies for the treatment of type 2 diabetes since June 2013. From March 2010 until December 2012 Mr. Hykes was the President and Chief Executive Officer at Cameron Health, Inc., an implantable defibrillator company, which was acquired by Boston Scientific Corporation in June 2012. From May 2008 to March 2010 Mr. Hykes served as the Chief Commercial Officer at Visiogen, Inc., a developer of products for cataract and refractive patients, which was acquired by Abbott Laboratories in October 2009. Previously, Mr. Hykes was employed by Medtronic, Inc., from 1992 to 2008 including as Vice President, Healthcare Systems, from December 2005 to May 2008 and as Vice President, Heart Failure Business, from May 2003 to December 2005. Mr. Hykes holds a B.A. in Business Administration from the University of Wisconsin, Madison and an M.B.A. from the J.L. Kellogg Graduate School of Management at Northwestern University. - Kevin Hykes,Hykes先生在自2009年7月起,一直是我们董事会的成员。Hykes先生目前是Versant Ventures的一名运营合伙人和Metavention, Inc.(一家发展早期的医疗设备公司,专注于研发2型糖尿病的介入治疗产品)的董事长和首席执行官。2010年3月到2012年12月期间,Hykes先生曾是 Cameron Health, Inc.(一家植入式除颤器公司,在2012年6月的时候被 Boston Scientific Corporation收购)的总裁和首席执行官;2008年5月到2010年3月期间,Hykes先生曾在Visiogen, Inc.(一家白内障和屈光患者产品的研发商,在2009年10月的时候被Abbott Laboratories收购)担任首席商务官。此前,Hykes先生曾在1992年到2008年期间受雇与Medtronic, Inc.,期间在2005年12月到2008年5月期间担任医疗卫生系统的副总裁;在2003年5月到2005年12月期间,担任心力衰竭相关业务的副总裁。Hykes先生拥有威斯康星大学麦迪逊分校(University of Wisconsin,Madison)的工商管理学士学位和西北大学凯洛格管理学院(the J.L. Kellogg Graduate School of Management at Northwestern University)的工商管理硕士学位。
- Kevin Hykes has served as a member of our Board since July 2009. Since August 2013 Mr. Hykes has served as an Operating Partner at Versant Ventures and the Chairman and CEO of Metavention, Inc., an early-stage medical device company focused on the development of interventional therapies for the treatment of type 2 diabetes since June 2013. From March 2010 until December 2012 Mr. Hykes was the President and Chief Executive Officer at Cameron Health, Inc., an implantable defibrillator company, which was acquired by Boston Scientific Corporation in June 2012. From May 2008 to March 2010 Mr. Hykes served as the Chief Commercial Officer at Visiogen, Inc., a developer of products for cataract and refractive patients, which was acquired by Abbott Laboratories in October 2009. Previously, Mr. Hykes was employed by Medtronic, Inc., from 1992 to 2008 including as Vice President, Healthcare Systems, from December 2005 to May 2008 and as Vice President, Heart Failure Business, from May 2003 to December 2005. Mr. Hykes holds a B.A. in Business Administration from the University of Wisconsin, Madison and an M.B.A. from the J.L. Kellogg Graduate School of Management at Northwestern University.
- William R. Rohn
-
William R. Rohn自2012年3月起一直担任Pfenex Inc.的一名董事。Rohn先生曾在2003年到2005年期间,担任Biogen Idec( IDEC Pharmaceuticals的继承公司,是一家生物技术公司)的首席运营官。1998年到2003年期间,Rohn先生是IDEC Pharmaceuticals(一家生物技术公司)的总裁和首席运营官。Rohn先生在1993年加入IDEC,担任它的商业和公司发展部的高级副总裁,并在1996年的时候被任命为商业运作部的高级副总裁。1985年到1993年期间,Rohn先生曾受雇与Adria Laboratories(一家制药公司,已经被Pfizer Inc.收购),最近担任的是销售和市场营销部的高级副总裁。Rohn先生现在还是Sophiris Bio Inc.和一些私营企业的董事。Rohn先生拥有密歇根州立大学(Michigan State University)的市场营销学士学位,并完成了印第安娜州立大学(Indiana State University)的工商管理研究生课程。
William R. Rohn joined Pfenex Inc.'s board of directors in 2014 and he is Pfenex Inc.'s board's Chairman. Most recently, Mr. Rohn served as Chief Operating Officer of Biogen Idec, the successor company to IDEC Pharmaceuticals, a biotechnology company, from 2003 until 2005. Mr. Rohn also held various management positions with IDEC Pharmaceuticals, a biotechnology company, including: President and Chief Operating Officer from 1998 to 2003 Senior Vice President, Commercial Operations from 1996 to 1998 and Senior Vice President, Commercial and Corporate Development from 1993 to 1996. He also held various management positions with Adria Laboratories, a pharmaceutical company acquired by Pfizer Inc., including Senior Vice President of Commercial Operations from 1991 to 1993 and Vice President of Business Development and Licensing from 1985 to 1990. Mr. Rohn currently serves on the board of directors of Hansen Medical, Inc., a medical device company. Mr. Rohn previously served on the boards of Intellikine, Inc., a pharmaceutical company acquired by Takeda America Holdings, Inc., Cerus Corporation, a biomedical products company, Elan Corporation, plc, a pharmaceutical company acquired by Perrigo Company plc, Metabasis Therapeutics, Inc., a biopharmaceutical company that merged with Ligand Pharmaceuticals Inc., Pharmacyclics Inc., a pharmaceutical company, Sophiris Bio Inc., a biopharmaceutical company, and Cebix Inc., a privately held biotechnology company. Mr. Rohn holds a Bachelor's degree in Marketing from Michigan State University and has completed graduate-level coursework in Business Administration at Indiana State University. - William R. Rohn自2012年3月起一直担任Pfenex Inc.的一名董事。Rohn先生曾在2003年到2005年期间,担任Biogen Idec( IDEC Pharmaceuticals的继承公司,是一家生物技术公司)的首席运营官。1998年到2003年期间,Rohn先生是IDEC Pharmaceuticals(一家生物技术公司)的总裁和首席运营官。Rohn先生在1993年加入IDEC,担任它的商业和公司发展部的高级副总裁,并在1996年的时候被任命为商业运作部的高级副总裁。1985年到1993年期间,Rohn先生曾受雇与Adria Laboratories(一家制药公司,已经被Pfizer Inc.收购),最近担任的是销售和市场营销部的高级副总裁。Rohn先生现在还是Sophiris Bio Inc.和一些私营企业的董事。Rohn先生拥有密歇根州立大学(Michigan State University)的市场营销学士学位,并完成了印第安娜州立大学(Indiana State University)的工商管理研究生课程。
- William R. Rohn joined Pfenex Inc.'s board of directors in 2014 and he is Pfenex Inc.'s board's Chairman. Most recently, Mr. Rohn served as Chief Operating Officer of Biogen Idec, the successor company to IDEC Pharmaceuticals, a biotechnology company, from 2003 until 2005. Mr. Rohn also held various management positions with IDEC Pharmaceuticals, a biotechnology company, including: President and Chief Operating Officer from 1998 to 2003 Senior Vice President, Commercial Operations from 1996 to 1998 and Senior Vice President, Commercial and Corporate Development from 1993 to 1996. He also held various management positions with Adria Laboratories, a pharmaceutical company acquired by Pfizer Inc., including Senior Vice President of Commercial Operations from 1991 to 1993 and Vice President of Business Development and Licensing from 1985 to 1990. Mr. Rohn currently serves on the board of directors of Hansen Medical, Inc., a medical device company. Mr. Rohn previously served on the boards of Intellikine, Inc., a pharmaceutical company acquired by Takeda America Holdings, Inc., Cerus Corporation, a biomedical products company, Elan Corporation, plc, a pharmaceutical company acquired by Perrigo Company plc, Metabasis Therapeutics, Inc., a biopharmaceutical company that merged with Ligand Pharmaceuticals Inc., Pharmacyclics Inc., a pharmaceutical company, Sophiris Bio Inc., a biopharmaceutical company, and Cebix Inc., a privately held biotechnology company. Mr. Rohn holds a Bachelor's degree in Marketing from Michigan State University and has completed graduate-level coursework in Business Administration at Indiana State University.
- Michael L. Eagle
-
Michael L. Eagle,Eagle先生自2012年2月起,一直担任我们董事会的成员;自2012年12月起,开始担任我们董事会的主席。Eagle先生曾在1993年到2001年期间,担任Eli Lilly and Company 的全球制造部的副总裁;曾在Eli Lilly and Company和它的子公司担任过许多执行管理阶层的职位。自从他从Eli Lilly and Company退休后,他成为了Barnard Life Sciences, LLC(一家生命科学咨询公司)的创始人之一。Eagle先生是 Cadence Pharmaceuticals, Inc.(一家生物制药公司)的董事会成员,并在它的审计委员会任职;还是Somaxon Pharmaceuticals, Inc.(一家专业制药公司)的董事会成员,并在它的审计和薪酬委员会任职。Eagle先生拥有凯特琳大学( Kettering University )的机械工程学士学位和普渡大学(Purdue University)的M.S.I.A。硕士学位。
Michael L. Eagle has served as a member of our Board since February 2012 and as the Chairman of our Board since December 2012. Mr. Eagle previously served as the Vice President of Global Manufacturing for Eli Lilly and Company from 1993 through 2001 and held a number of executive management positions with Eli Lilly and Company and its subsidiaries throughout his career there. Since retiring from Eli Lilly and Company, he has been a founding member of Barnard Life Sciences, LLC, a life sciences consulting company. Mr. Eagle was a member of the board of directors and served on the audit committee of Cadence Pharmaceuticals, Inc., a biopharmaceutical company, from 2010 through 2014 and was a member of the board of directors and served on the audit and compensation committees of Somaxon Pharmaceuticals, Inc., a specialty pharmaceutical company from 2007 through 2013. Mr. Eagle holds a B.M.E. from Kettering University and an M.S.I.A. from Purdue University. - Michael L. Eagle,Eagle先生自2012年2月起,一直担任我们董事会的成员;自2012年12月起,开始担任我们董事会的主席。Eagle先生曾在1993年到2001年期间,担任Eli Lilly and Company 的全球制造部的副总裁;曾在Eli Lilly and Company和它的子公司担任过许多执行管理阶层的职位。自从他从Eli Lilly and Company退休后,他成为了Barnard Life Sciences, LLC(一家生命科学咨询公司)的创始人之一。Eagle先生是 Cadence Pharmaceuticals, Inc.(一家生物制药公司)的董事会成员,并在它的审计委员会任职;还是Somaxon Pharmaceuticals, Inc.(一家专业制药公司)的董事会成员,并在它的审计和薪酬委员会任职。Eagle先生拥有凯特琳大学( Kettering University )的机械工程学士学位和普渡大学(Purdue University)的M.S.I.A。硕士学位。
- Michael L. Eagle has served as a member of our Board since February 2012 and as the Chairman of our Board since December 2012. Mr. Eagle previously served as the Vice President of Global Manufacturing for Eli Lilly and Company from 1993 through 2001 and held a number of executive management positions with Eli Lilly and Company and its subsidiaries throughout his career there. Since retiring from Eli Lilly and Company, he has been a founding member of Barnard Life Sciences, LLC, a life sciences consulting company. Mr. Eagle was a member of the board of directors and served on the audit committee of Cadence Pharmaceuticals, Inc., a biopharmaceutical company, from 2010 through 2014 and was a member of the board of directors and served on the audit and compensation committees of Somaxon Pharmaceuticals, Inc., a specialty pharmaceutical company from 2007 through 2013. Mr. Eagle holds a B.M.E. from Kettering University and an M.S.I.A. from Purdue University.
- Nadim Yared
-
Nadim Yared,Yared先生自2012年7月以来一直担任我们董事会的成员。Yared先生在医疗设备行业已经工作了将近20年。他目前是在担任CVRx, Inc.(一家私营的医疗设备公司,研发用于治疗高血压和心脏衰竭的植入式设备)的总裁和首席执行官。他在这个职位上工作了7年,在这7年的时间里,Yared先生协助CRVx筹集大笔资金来研发公司的下一代技术并进行临床试验。在他在CVRx任职期间之前,Yared先生曾在Medtronic, Inc.担任了4年的副总裁和总经理。在他任职期间,他领导着销售和市场营销,业务发展,外科医疗影像产品/技术开发和制造。在2002年之前,Yared先生曾在GE Medical Systems工作了9年多,并在这段期间担任了各种高级职位。他在这段期间最主要是负责医疗设备销售和市场营销管理。Yared先生目前在医疗设备行业交易集团,AdvaMedand te medical device innovation consortium, MDIC(一家公私合营企业)的董事会任职。Yared先生拥有法国巴黎的欧洲工商管理学院的工商管理硕士学位和 Ecole Nationale Superieure des Telecommunications的工程学学位。
Nadim Yared has served as a member of our Board since July 2012. Mr. Yared’s career in the medical device industry has spanned nearly 20 years. He has served as the President and Chief Executive Officer of CVRx, Inc. since September 2006. CVRx is a privately-held medical device company developing the Barostim neo™ system, an active implantable device for the treatment of hypertension and heart failure. Mr. Yared has helped CVRx raise significant funding to develop the company’s next generation technology and conduct clinical trials. Preceding his term at CVRx, Mr. Yared served as Vice President and General Manager of Medtronic, Inc. for four years. During his tenure, he directed sales, marketing, business development, product/technology development and manufacturing of surgical medical imaging products. Until 2002 Mr. Yared held increasingly senior positions at GE Medical Systems over a period of nine years. Much of his focus during this time was medical device sales and marketing management. Mr. Yared also currently serves on the boards of the medical device industry trade group, AdvaMed and the medical device innovation consortium, MDIC, a public-private partnership. Mr. Yared holds an M.B.A. from Insead in Paris, France, and an engineering degree from Ecole Nationale Superieure des Telecommunications. - Nadim Yared,Yared先生自2012年7月以来一直担任我们董事会的成员。Yared先生在医疗设备行业已经工作了将近20年。他目前是在担任CVRx, Inc.(一家私营的医疗设备公司,研发用于治疗高血压和心脏衰竭的植入式设备)的总裁和首席执行官。他在这个职位上工作了7年,在这7年的时间里,Yared先生协助CRVx筹集大笔资金来研发公司的下一代技术并进行临床试验。在他在CVRx任职期间之前,Yared先生曾在Medtronic, Inc.担任了4年的副总裁和总经理。在他任职期间,他领导着销售和市场营销,业务发展,外科医疗影像产品/技术开发和制造。在2002年之前,Yared先生曾在GE Medical Systems工作了9年多,并在这段期间担任了各种高级职位。他在这段期间最主要是负责医疗设备销售和市场营销管理。Yared先生目前在医疗设备行业交易集团,AdvaMedand te medical device innovation consortium, MDIC(一家公私合营企业)的董事会任职。Yared先生拥有法国巴黎的欧洲工商管理学院的工商管理硕士学位和 Ecole Nationale Superieure des Telecommunications的工程学学位。
- Nadim Yared has served as a member of our Board since July 2012. Mr. Yared’s career in the medical device industry has spanned nearly 20 years. He has served as the President and Chief Executive Officer of CVRx, Inc. since September 2006. CVRx is a privately-held medical device company developing the Barostim neo™ system, an active implantable device for the treatment of hypertension and heart failure. Mr. Yared has helped CVRx raise significant funding to develop the company’s next generation technology and conduct clinical trials. Preceding his term at CVRx, Mr. Yared served as Vice President and General Manager of Medtronic, Inc. for four years. During his tenure, he directed sales, marketing, business development, product/technology development and manufacturing of surgical medical imaging products. Until 2002 Mr. Yared held increasingly senior positions at GE Medical Systems over a period of nine years. Much of his focus during this time was medical device sales and marketing management. Mr. Yared also currently serves on the boards of the medical device industry trade group, AdvaMed and the medical device innovation consortium, MDIC, a public-private partnership. Mr. Yared holds an M.B.A. from Insead in Paris, France, and an engineering degree from Ecole Nationale Superieure des Telecommunications.
- Stephen Newman
-
Stephen Newman,Newman博士自2012年7月起,一直是我们董事会的成员。在Tenet Healthcare Corporation 工作了14年多,担任高级阶层职位,Newman博士在医疗卫生运营行业收获了丰的经验。在他最近刚卸任的董事长的职位上,Newman博士领导了Tenet的卫生信息技术项目的部署工作,公司医务人员发展工作和它的质量,安全以及服务管理。在他在2012年1月担任副董事长之前,Newman博士曾担任了5年的公司首席运营官和执行副总裁,负责包括Tenet的49家的医院和100家的门诊成像中心的战略和业务监管。在他在Tenet任职之前,Newman博士曾在HCA's Louisville HealthCare Network担任总裁和首席执行官,负责一项5亿美元的业务中的3家医院和3000个职工的事务。Newman博士目前在Cadence Pharmaceuticals, Inc.的董事会任职,并且是它的提名和公司治理委员会的委员。Newman博士在2012年到2013年10月期间,曾在 Optimer Pharmaceuticals, Inc.的董事会任职,并且是它的审计委员会,薪酬委员会和提名与公司治理委员会的委员。Newman博士目前还在亚特兰大的劳动,教育和医疗保健委员会的联邦储备银行工作,最近完成了在the Federation of American Hospitals的董事会的5年任期工作。Newman博士拥有杜兰大学AB弗里曼商学院(Tulane University's AB Freeman School of Business)的工商管理硕士学位和田纳西大学健康科学中心(the University of Tennessee Center for Health Sciences)的医学博士学位以及罗格斯大学(Rutgers University)的学士学位。
Stephen Newman has served as a member of our Board since July 2012. Having served in increasingly senior positions at Tenet Healthcare Corporation over the past 14 years, Dr. Newman has extensive healthcare operations experience. Dr. Newman was the Vice Chairman of Tenet Healthcare Corporation from January 2012 until June 2012. In that role, Dr. Newman led Tenet’s health information technology project deployment, the company’s medical staff development efforts and its quality, safety and service initiative. Prior to his appointment to Vice Chairman in January 2012 Dr. Newman served as Corporate Chief Operating Officer, Executive Vice President from January 2007 through December 2011 where his responsibilities included strategic and operational oversight of Tenet’s 49 hospitals and 100 ambulatory and imaging centers. Before his tenure at Tenet, Dr. Newman served as President and Chief Executive Officer of HCA’s Louisville HealthCare Network, where he had operating responsibilities for three hospitals and 3000 employees within a $500 million business. Dr. Newman served on the board of directors of Cadence Pharmaceuticals, Inc. and was member of its nominating and corporate governance committee from 2013 through 2014. Dr. Newman served on the board of directors of Optimer Pharmaceuticals, Inc. from 2012 through October 2013 and was a member of its audit committee, compensation committee and nominating and corporate governance committee. Dr. Newman also currently serves on the Federal Reserve Bank of Atlanta’s Labor, Education and Healthcare Council and recently completed a five year term on the board of directors of the Federation of American Hospitals. Dr. Newman holds an M.B.A. from Tulane University’s AB Freeman School of Business, an M.D. from the University of Tennessee Center for Health Sciences and a Bachelor’s degree from Rutgers University. - Stephen Newman,Newman博士自2012年7月起,一直是我们董事会的成员。在Tenet Healthcare Corporation 工作了14年多,担任高级阶层职位,Newman博士在医疗卫生运营行业收获了丰的经验。在他最近刚卸任的董事长的职位上,Newman博士领导了Tenet的卫生信息技术项目的部署工作,公司医务人员发展工作和它的质量,安全以及服务管理。在他在2012年1月担任副董事长之前,Newman博士曾担任了5年的公司首席运营官和执行副总裁,负责包括Tenet的49家的医院和100家的门诊成像中心的战略和业务监管。在他在Tenet任职之前,Newman博士曾在HCA's Louisville HealthCare Network担任总裁和首席执行官,负责一项5亿美元的业务中的3家医院和3000个职工的事务。Newman博士目前在Cadence Pharmaceuticals, Inc.的董事会任职,并且是它的提名和公司治理委员会的委员。Newman博士在2012年到2013年10月期间,曾在 Optimer Pharmaceuticals, Inc.的董事会任职,并且是它的审计委员会,薪酬委员会和提名与公司治理委员会的委员。Newman博士目前还在亚特兰大的劳动,教育和医疗保健委员会的联邦储备银行工作,最近完成了在the Federation of American Hospitals的董事会的5年任期工作。Newman博士拥有杜兰大学AB弗里曼商学院(Tulane University's AB Freeman School of Business)的工商管理硕士学位和田纳西大学健康科学中心(the University of Tennessee Center for Health Sciences)的医学博士学位以及罗格斯大学(Rutgers University)的学士学位。
- Stephen Newman has served as a member of our Board since July 2012. Having served in increasingly senior positions at Tenet Healthcare Corporation over the past 14 years, Dr. Newman has extensive healthcare operations experience. Dr. Newman was the Vice Chairman of Tenet Healthcare Corporation from January 2012 until June 2012. In that role, Dr. Newman led Tenet’s health information technology project deployment, the company’s medical staff development efforts and its quality, safety and service initiative. Prior to his appointment to Vice Chairman in January 2012 Dr. Newman served as Corporate Chief Operating Officer, Executive Vice President from January 2007 through December 2011 where his responsibilities included strategic and operational oversight of Tenet’s 49 hospitals and 100 ambulatory and imaging centers. Before his tenure at Tenet, Dr. Newman served as President and Chief Executive Officer of HCA’s Louisville HealthCare Network, where he had operating responsibilities for three hospitals and 3000 employees within a $500 million business. Dr. Newman served on the board of directors of Cadence Pharmaceuticals, Inc. and was member of its nominating and corporate governance committee from 2013 through 2014. Dr. Newman served on the board of directors of Optimer Pharmaceuticals, Inc. from 2012 through October 2013 and was a member of its audit committee, compensation committee and nominating and corporate governance committee. Dr. Newman also currently serves on the Federal Reserve Bank of Atlanta’s Labor, Education and Healthcare Council and recently completed a five year term on the board of directors of the Federation of American Hospitals. Dr. Newman holds an M.B.A. from Tulane University’s AB Freeman School of Business, an M.D. from the University of Tennessee Center for Health Sciences and a Bachelor’s degree from Rutgers University.
- Marjorie L. Bowen
-
Marjorie L. Bowen自2013年7月起,一直是我们董事会的一名成员。Bowen女士是一名经理丰富的上市和私营公司董事,是一名有资质的财务专家,并且十分擅长公司治理的事务。除了在Hansen之外,Bowen女士还在四家上市公司( Dune Energy , Illinois Power Generating Co., Talbots 和 Texas Industries, Inc.)以及四家私营公司担任一名董事。Bowen女士将近20年的职业生涯中的担任董事的经历包括在 Houlihan Lokey的投资银行业和在一些上市公司的咨询委员会处理新交易,战略和其他股东事务,并领导着公司的工业主要公平意见操作。在她在Houilhan Lokey的将近年时间中,Bowen女士曾活跃于上市公司董事会,担任交易顾问;生产和业务领导人以及公司高级管理阶层的人员。Bowen女士在良好和陷入困境的公司的几乎所有类型的金融交易中积累了丰富的经验。Bowen女士拥有科尔盖特大学(Colgate University )的学士学位和芝加哥大学(the University of Chicago)的工商管理硕士学位。
Marjorie L. Bowen,Retired Managing Director, Houlihan Lokey. Ms. Bowen joined Genesco’s board in April 2018. Ms. Bowen was an investment banker with Houlihan Lokey from 1989 until 2007 serving as managing director since 1997. Ms. Bowen also has served as special independent director on the board of Illinois Power Generating Company a subsidiary of Dynegy since December 2013 and serves as a director for two privately held companies, SquareTwo Financial and OmniForce Holdings. Recently, Ms. Bowen served as the audit committee chair on the board of Hansen Medical, Inc. and previously served on the boards of six other public and private companies, including as a director of Global Aviation Holdings from 2008 to 2014 and as a director of The Talbots, Inc. from 2010 to 2012. - Marjorie L. Bowen自2013年7月起,一直是我们董事会的一名成员。Bowen女士是一名经理丰富的上市和私营公司董事,是一名有资质的财务专家,并且十分擅长公司治理的事务。除了在Hansen之外,Bowen女士还在四家上市公司( Dune Energy , Illinois Power Generating Co., Talbots 和 Texas Industries, Inc.)以及四家私营公司担任一名董事。Bowen女士将近20年的职业生涯中的担任董事的经历包括在 Houlihan Lokey的投资银行业和在一些上市公司的咨询委员会处理新交易,战略和其他股东事务,并领导着公司的工业主要公平意见操作。在她在Houilhan Lokey的将近年时间中,Bowen女士曾活跃于上市公司董事会,担任交易顾问;生产和业务领导人以及公司高级管理阶层的人员。Bowen女士在良好和陷入困境的公司的几乎所有类型的金融交易中积累了丰富的经验。Bowen女士拥有科尔盖特大学(Colgate University )的学士学位和芝加哥大学(the University of Chicago)的工商管理硕士学位。
- Marjorie L. Bowen,Retired Managing Director, Houlihan Lokey. Ms. Bowen joined Genesco’s board in April 2018. Ms. Bowen was an investment banker with Houlihan Lokey from 1989 until 2007 serving as managing director since 1997. Ms. Bowen also has served as special independent director on the board of Illinois Power Generating Company a subsidiary of Dynegy since December 2013 and serves as a director for two privately held companies, SquareTwo Financial and OmniForce Holdings. Recently, Ms. Bowen served as the audit committee chair on the board of Hansen Medical, Inc. and previously served on the boards of six other public and private companies, including as a director of Global Aviation Holdings from 2008 to 2014 and as a director of The Talbots, Inc. from 2010 to 2012.
高管简历
中英对照 |  中文 |  英文- Cary G. Vance
Cary G. Vance,2014年5月起,担任本公司的总裁、首席执行官、董事。2011年5月至2014年5月,他担任Teleflex Incorporated麻醉和呼吸的全球业务总裁,这是专有医疗器械公司;2010年2月至2011年5月,担任北美地区执行副总裁。他于2007年加入Covidien,担任副总裁、基于能源设备的总经理,这是全球性的医疗保健产品制造商;2008年,担任副总裁、美洲地区介入式肿瘤总经理。1997-2007,他在 GE Healthcare担任了愈益重要的多个职务,主要涉及诊断成像的销售、销售与营销管理、执行领导。他在Marquette University获得经济学士学位、工商管理硕士学位。
Cary G. Vance has served as our President and Chief Executive Officer, and as a member of our Board, since May 2014. Mr. Vance served as President of the Anesthesia & Respiratory global business at Teleflex Incorporated, a specialty medical device company, from May 2011 until May 2014 and as their Executive Vice President North America from February 2010 to May 2011. Mr. Vance joined Covidien, a global health care products company and manufacturer, in 2007 as Vice President & General Manager for their Energy-based Devices and was appointed as Vice President & General Manager of Interventional Oncology - Americas in 2008. Mr. Vance served in a series of roles with progressive responsibility at GE Healthcare from 1997 to 2007 principally in diagnostic imaging sales, sales and marketing management and executive leadership. Mr. Vance holds a B.A. in Economics and an M.B.A. from Marquette University. Mr. Vance’s executive experience in the medical device space contributed to our conclusion that he should serve as a director.- Cary G. Vance,2014年5月起,担任本公司的总裁、首席执行官、董事。2011年5月至2014年5月,他担任Teleflex Incorporated麻醉和呼吸的全球业务总裁,这是专有医疗器械公司;2010年2月至2011年5月,担任北美地区执行副总裁。他于2007年加入Covidien,担任副总裁、基于能源设备的总经理,这是全球性的医疗保健产品制造商;2008年,担任副总裁、美洲地区介入式肿瘤总经理。1997-2007,他在 GE Healthcare担任了愈益重要的多个职务,主要涉及诊断成像的销售、销售与营销管理、执行领导。他在Marquette University获得经济学士学位、工商管理硕士学位。
- Cary G. Vance has served as our President and Chief Executive Officer, and as a member of our Board, since May 2014. Mr. Vance served as President of the Anesthesia & Respiratory global business at Teleflex Incorporated, a specialty medical device company, from May 2011 until May 2014 and as their Executive Vice President North America from February 2010 to May 2011. Mr. Vance joined Covidien, a global health care products company and manufacturer, in 2007 as Vice President & General Manager for their Energy-based Devices and was appointed as Vice President & General Manager of Interventional Oncology - Americas in 2008. Mr. Vance served in a series of roles with progressive responsibility at GE Healthcare from 1997 to 2007 principally in diagnostic imaging sales, sales and marketing management and executive leadership. Mr. Vance holds a B.A. in Economics and an M.B.A. from Marquette University. Mr. Vance’s executive experience in the medical device space contributed to our conclusion that he should serve as a director.
- Brian Sheahan
Brian Sheahan,2014年10月加入Hansen 并担任临床、监管和质量事务副总裁。他有着超过25年的医疗设备行业经验。2006年4月-2014年10月,他在一家专注于开发心脏瓣膜技术- Direct Flow Medical, Inc.担任临床和监管事务、质量保证高级副总裁。
Brian Sheahan joined Hansen in October 2014 as Vice President of Clinical, Regulatory and Quality Affairs. Mr. Sheahan has over 25 years of experience in the medical device field. From April 2006 to October 2014 he served as Senior Vice President of Clinical and Regulatory Affairs and Quality Assurance for Direct Flow Medical, Inc., a company focused on developing heart valve technologies.- Brian Sheahan,2014年10月加入Hansen 并担任临床、监管和质量事务副总裁。他有着超过25年的医疗设备行业经验。2006年4月-2014年10月,他在一家专注于开发心脏瓣膜技术- Direct Flow Medical, Inc.担任临床和监管事务、质量保证高级副总裁。
- Brian Sheahan joined Hansen in October 2014 as Vice President of Clinical, Regulatory and Quality Affairs. Mr. Sheahan has over 25 years of experience in the medical device field. From April 2006 to October 2014 he served as Senior Vice President of Clinical and Regulatory Affairs and Quality Assurance for Direct Flow Medical, Inc., a company focused on developing heart valve technologies.
- Christopher P. Lowe
Christopher P. Lowe, 他一直担任我们的董事会成员(2006年9月以来),以及我们的临时首席执行官(2014年2月以来)。他曾担任Anthera Pharmaceuticals公司(药物开发公司)的行政副总裁和首席财务官(从2007年11月到2013年6月),以及其首席商务官(从2011年1月到2013年6月)。离开Anthera公司以后,他曾担任生命科学公司的独立顾问,直到加入FLG Partners公司(首席财务官咨询、服务和咨询公司),并于2014年1月当选合伙人。他曾担任Asthmatx公司(医疗器械公司)的副总裁,负责财务和行政(2005年9月以来),以及其首席财务官(从2006年1月到2007年11月)。他也曾任职Pacific Pharmaceutical Services公司(cGMP实体,提供温度控制存储、粉调剂、内部标签印刷和临床试验材料标签、临床销售物流和CMC咨询服务,服务制药行业、临床研究和学术实验室)的董事会。他持有California Polytechnic State University(位于圣路易斯奥比斯波)的学士学位,以及Saint Mary’s University(位于德克萨斯)的工商管理硕士学位。
Christopher P. Lowe has served as a member of our Board since September 2006 as our Interim Chief Executive Officer from February 2014 to May 2014 and our Interim Chief Financial Officer since June 2014. Mr. Lowe served as Vice President, Administration and Chief Financial Officer of Anthera Pharmaceuticals, Inc., a drug development company, from November 2007 through June 2013 and additionally served as its Chief Business Officer from January 2011 until June 2013. Since leaving Anthera, Mr. Lowe was an independent consultant to life sciences companies until joining FLG Partners, LLC, a CFO consulting, services and board advisory firm, as a partner in January 2014. Mr. Lowe served as Vice President, Finance and Administration of Asthmatx, Inc., a medical device company, since September 2005 and as its Chief Financial Officer from January 2006 to November 2007. Mr. Lowe also serves on the board of Pacific Pharmaceutical Services, a cGMP facility providing temperature controlled storage, powder dispensing, in-house label printing and clinical trial materials labeling, clinical distribution logistics and CMC advisory services to the pharmaceutical industry, clinical researchers and academic laboratories. Mr. Lowe holds a B.S. from California Polytechnic State University, San Luis Obispo and an M.B.A. from Saint Mary’s University, Texas.- Christopher P. Lowe, 他一直担任我们的董事会成员(2006年9月以来),以及我们的临时首席执行官(2014年2月以来)。他曾担任Anthera Pharmaceuticals公司(药物开发公司)的行政副总裁和首席财务官(从2007年11月到2013年6月),以及其首席商务官(从2011年1月到2013年6月)。离开Anthera公司以后,他曾担任生命科学公司的独立顾问,直到加入FLG Partners公司(首席财务官咨询、服务和咨询公司),并于2014年1月当选合伙人。他曾担任Asthmatx公司(医疗器械公司)的副总裁,负责财务和行政(2005年9月以来),以及其首席财务官(从2006年1月到2007年11月)。他也曾任职Pacific Pharmaceutical Services公司(cGMP实体,提供温度控制存储、粉调剂、内部标签印刷和临床试验材料标签、临床销售物流和CMC咨询服务,服务制药行业、临床研究和学术实验室)的董事会。他持有California Polytechnic State University(位于圣路易斯奥比斯波)的学士学位,以及Saint Mary’s University(位于德克萨斯)的工商管理硕士学位。
- Christopher P. Lowe has served as a member of our Board since September 2006 as our Interim Chief Executive Officer from February 2014 to May 2014 and our Interim Chief Financial Officer since June 2014. Mr. Lowe served as Vice President, Administration and Chief Financial Officer of Anthera Pharmaceuticals, Inc., a drug development company, from November 2007 through June 2013 and additionally served as its Chief Business Officer from January 2011 until June 2013. Since leaving Anthera, Mr. Lowe was an independent consultant to life sciences companies until joining FLG Partners, LLC, a CFO consulting, services and board advisory firm, as a partner in January 2014. Mr. Lowe served as Vice President, Finance and Administration of Asthmatx, Inc., a medical device company, since September 2005 and as its Chief Financial Officer from January 2006 to November 2007. Mr. Lowe also serves on the board of Pacific Pharmaceutical Services, a cGMP facility providing temperature controlled storage, powder dispensing, in-house label printing and clinical trial materials labeling, clinical distribution logistics and CMC advisory services to the pharmaceutical industry, clinical researchers and academic laboratories. Mr. Lowe holds a B.S. from California Polytechnic State University, San Luis Obispo and an M.B.A. from Saint Mary’s University, Texas.
- Robert Cathcart
Robert Cathcart在2013年1月加入Hansen,担任全球销售部的高级副总裁。在加入Hansen之前,Cathcart先生曾在2011年10月到2012年4月期间,担任HyperBranch Medical Technology(一家外科医疗设备公司)的首席商务官。在2009年4月到2011年8月期间,他曾担任FlowCo, Inc./3DT Holdings(一家私营的医疗设备公司,主要是关注介入心脏病方面的)的总裁和首席执行官。2001年到2009年期间,Cathcart先生曾在 Datascope Corporation (现已被Maquet收购)工作,担任部门总裁和心脏辅助产品部门的销售副总裁,之后是担任介入性产品部门的总裁。Cathcart先生还在 Promedix Inc., Bard Access Systems 和 MedChem Products这三家机构担任销售方面的职位。他是在Davis + Geck开始自己的职业生涯,并在此担任销售代表,全球培训经理,区域经理,最后担任的是内镜外科手术部的区域主任。Cathcart先生拥有迪堡大学(DePauw University)的文学士学位。
Robert Cathcart joined Hansen in January 2013 as Senior Vice President of Global Sales. Prior to joining Hansen, Mr. Cathcart served as the Chief Commercial Officer of HyperBranch Medical Technology, a surgical medical device company, from October 2011 until April 2012. From April 2009 to August 2011 he served as the President and CEO of FlowCo, Inc./3DT Holdings, a privately-held medical device company focused on interventional cardiology. From 2001 to 2009 Mr. Cathcart worked at Datascope Corporation acquired by Maquet; where he served as the Division President and Vice President of Sales in the Cardiac Assist Division, and later the President of the Interventional Products Division. Mr. Cathcart has also led the sales functions of Promedix Inc., Bard Access Systems and MedChem Products. He began his career at Davis + Geck, where he served as a sales representative, global training manager, regional manager, and eventually area director of the endo-surgery division. Mr. Cathcart holds a Bachelor of Arts degree from DePauw University.- Robert Cathcart在2013年1月加入Hansen,担任全球销售部的高级副总裁。在加入Hansen之前,Cathcart先生曾在2011年10月到2012年4月期间,担任HyperBranch Medical Technology(一家外科医疗设备公司)的首席商务官。在2009年4月到2011年8月期间,他曾担任FlowCo, Inc./3DT Holdings(一家私营的医疗设备公司,主要是关注介入心脏病方面的)的总裁和首席执行官。2001年到2009年期间,Cathcart先生曾在 Datascope Corporation (现已被Maquet收购)工作,担任部门总裁和心脏辅助产品部门的销售副总裁,之后是担任介入性产品部门的总裁。Cathcart先生还在 Promedix Inc., Bard Access Systems 和 MedChem Products这三家机构担任销售方面的职位。他是在Davis + Geck开始自己的职业生涯,并在此担任销售代表,全球培训经理,区域经理,最后担任的是内镜外科手术部的区域主任。Cathcart先生拥有迪堡大学(DePauw University)的文学士学位。
- Robert Cathcart joined Hansen in January 2013 as Senior Vice President of Global Sales. Prior to joining Hansen, Mr. Cathcart served as the Chief Commercial Officer of HyperBranch Medical Technology, a surgical medical device company, from October 2011 until April 2012. From April 2009 to August 2011 he served as the President and CEO of FlowCo, Inc./3DT Holdings, a privately-held medical device company focused on interventional cardiology. From 2001 to 2009 Mr. Cathcart worked at Datascope Corporation acquired by Maquet; where he served as the Division President and Vice President of Sales in the Cardiac Assist Division, and later the President of the Interventional Products Division. Mr. Cathcart has also led the sales functions of Promedix Inc., Bard Access Systems and MedChem Products. He began his career at Davis + Geck, where he served as a sales representative, global training manager, regional manager, and eventually area director of the endo-surgery division. Mr. Cathcart holds a Bachelor of Arts degree from DePauw University.